Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
          • Financials
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • What is a Clinical Trial?
          • Your Involvement Matters
          • Current Trials & Studies
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • World FSHD Day
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Current Trials and Studies
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • Search
  • Financials
  • Patient Library
  • Blog
  • Calendar
  • JOIN US
  • Donate
  • JOIN US
  • Donate

Losmapimod receives orphan drug designation

Home / FSHD Research / Losmapimod receives orphan drug designation

Posted on: Feb 04, 2020

Fulcrum LogoFulcrum Therapeutics has announced that losmapimod has received orphan drug designation from the U.S. Food and Drug Administration. Losmapimod is currently in a Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD). The drug qualified for this status because FSHD, with an estimated 20-40,000 affected individuals in the U.S., is considered a rare disease. (The FDA defines conditions that affect fewer than 200,000 people in the U.S. as rare diseases.)

What does this mean for patients?

The orphan designation grants the company seven years of market exclusivity following FDA approval (if received), exemption of FDA application fees, and tax credits for qualified clinical trials. This helps the bottom line and makes Fulcrum more attractive to investors. It’s good for patients indirectly, in that it helps the company from a business standpoint. But the orphan drug designation will not get losmapimod to patients any faster. The drug still needs to get through clinical trial(s) and the FDA approval process.

The true inflection point for patients would be if the FDA grants what is called an accelerated approval. This might be considered if the Phase 2 trial clearly shows that losmapimod reduces the activity of the gene DUX4. If the FDA accepts the argument that the drug is therefore likely to slow down disease progression, and that it has been shown to be safe, the agency might grant an accelerated approval on that basis.

The soonest that the FDA could consider an accelerated approval would be after the Phase 2 trial has been completed, a milestone that Fulcrum expects to reach in the third quarter of 2020. And there is no guarantee. The Phase 2 data might not support an approval, or the FDA might require a larger, Phase 3 trial. We will be following developments closely!

For more information, visit our page about clinical trials. For more information about orphan designation, please visit the FDA website at www.fda.gov.

Share

Filed Under: FSHD Research

Comments

  1. Susan Meade says

    February 5, 2020 at 10:42 pm

    Potentially wonderful news for our 23 yr old grandson! Can you tell us anymore about this treatment? How is it administered, what results are seen so far, etc.

    Reply
    • jkinoshita says

      February 6, 2020 at 10:22 am

      Losmapimod is given as a pill taken twice a day. It is currently in a Phase 2 clinical trial. Results will not be known until the trial has been completed (anticipated for summer 2020) and the data have been analyzed.

      Reply
  2. Birgitte says

    February 13, 2020 at 7:45 am

    When will the drug be available in Europe? I look forward to this treatment as I expect all others with FSHD will. It is frustrating to have an illness that cannot be treated.

    Reply
  3. Jories says

    March 3, 2020 at 3:15 pm

    The drug is currently being trialed by Fulcrum in the Netherlands (University of Nijmegen).

    See: https://www.clinicaltrials.gov/ct2/show/NCT04004000?term=losmapimod&cond=fshd&draw=2&rank=3

    Reply
  4. Jeannine Asselin says

    March 11, 2020 at 12:42 pm

    What about Canada? Is it available?

    Reply
    • jkinoshita says

      March 14, 2020 at 10:26 am

      Losmapimod is not yet approved so it’s not available in Canada either.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

FSHD Society
P.O. Box 411617
Boston, MA 02241-1617

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by